Stoke Therapeutics, Inc. (STOK) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17
	10-K	10-K	10-K	10-K	10-K	S-1/A
Revenues [+]	12.4	0.0	0.0	0.0	0.0	3.6
Royalties						3.6
Revenue growth					-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	5.6
Gross profit	12.4	0.0	0.0	0.0	0.0	-2.0
Gross margin	100.0%					-54.4%
Selling, general and administrative [+]	38.9	31.9	20.8	11.9	4.4	2.0
General and administrative	38.9	31.9	20.8	11.9	4.4	2.0
Research and development	77.8	54.2	32.2	23.8	8.4
Other operating expenses						1.6
EBITDA [+]	-102.8	-85.1	-52.2	-35.2	-12.6	-5.4
EBITDA growth	20.8%	63.1%	48.1%	180.3%	131.0%
EBITDA margin	-828.8%					-151.2%
Depreciation and amortization	1.5	1.0	0.9	0.5	0.2	0.1
EBIT [+]	-104.4	-86.1	-53.0	-35.7	-12.8	-5.6
EBIT growth	21.3%	62.3%	48.7%	179.1%	130.1%
EBIT margin	-841.2%					-154.4%
Interest income	3.1	0.1	0.7	3.4	0.3
Interest income	3.1	0.1	0.7	3.4	0.3
Other income (expense), net	0.2	0.1	0.1	0.0	0.0	0.0
Pre-tax income	-101.1	-85.8	-52.2	-32.3	-12.5	-5.6
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-101.1	-85.8	-52.2	-32.3	-12.5	-5.6
Net margin	-814.7%					-154.5%

Basic EPS [+]	($2.60)	($2.34)	($1.56)	($1.80)	($17.65)	($8.29)
Growth	11.3%	49.7%	-13.3%	-89.8%	112.8%
Diluted EPS [+]	($2.60)	($2.34)	($1.56)	($1.80)	($17.65)	($8.29)
Growth	11.3%	49.7%	-13.3%	-89.8%	112.8%

Shares outstanding (basic) [+]	38.9	36.7	33.5	18.0	0.7	0.7
Growth	5.9%	9.7%	86.3%	2433.6%	5.9%
Shares outstanding (diluted) [+]	38.9	36.7	33.5	18.0	0.7	0.7
Growth	5.9%	9.7%	86.3%	2433.6%	5.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.